C. Leonardi

3.7k total citations
57 papers, 2.1k citations indexed

About

C. Leonardi is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, C. Leonardi has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 25 papers in Dermatology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in C. Leonardi's work include Psoriasis: Treatment and Pathogenesis (36 papers), Dermatology and Skin Diseases (21 papers) and Autoimmune Bullous Skin Diseases (12 papers). C. Leonardi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (36 papers), Dermatology and Skin Diseases (21 papers) and Autoimmune Bullous Skin Diseases (12 papers). C. Leonardi collaborates with scholars based in United States, Canada and Germany. C. Leonardi's co-authors include Alan Menter, Andrew Blauvelt, Kristian Reich, Alice B. Gottlieb, George T. Nahass, Robert W. Rubin, C.E.M. Griffiths, Kim Papp, Neal S. Penneys and Francisco A. Kerdel and has published in prestigious journals such as Methods in enzymology on CD-ROM/Methods in enzymology, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

C. Leonardi

55 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Leonardi United States	26	1.6k	969	344	309	298	57	2.1k
Enrique Rivas Mexico	9	1.4k 0.9×	763 0.8×	337 1.0×	178 0.6×	250 0.8×	13	1.7k
Silvia Helou Argentina	10	1.3k 0.8×	727 0.8×	332 1.0×	326 1.1×	245 0.8×	16	1.7k
J.‐H. Saurat Switzerland	25	927 0.6×	908 0.9×	581 1.7×	319 1.0×	600 2.0×	77	2.3k
Elisabeth Riedl Austria	23	1.8k 1.2×	693 0.7×	169 0.5×	320 1.0×	153 0.5×	63	2.7k
Marc Bourcier Canada	20	738 0.5×	734 0.8×	128 0.4×	291 0.9×	155 0.5×	42	1.2k
Bruce Miller United States	18	507 0.3×	540 0.6×	188 0.5×	156 0.5×	177 0.6×	32	1.1k
Wynnis L. Tom United States	19	421 0.3×	947 1.0×	172 0.5×	105 0.3×	159 0.5×	60	1.7k
Furen Zhang China	19	445 0.3×	369 0.4×	262 0.8×	290 0.9×	172 0.6×	118	1.5k
Hong‐Shang Hong Taiwan	19	227 0.1×	693 0.7×	513 1.5×	327 1.1×	605 2.0×	67	2.4k
Marek Karczewski Poland	12	878 0.6×	141 0.1×	257 0.7×	278 0.9×	112 0.4×	48	1.6k

Countries citing papers authored by C. Leonardi

Since Specialization

Citations

This map shows the geographic impact of C. Leonardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Leonardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Leonardi more than expected).

Fields of papers citing papers by C. Leonardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Leonardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Leonardi. The network helps show where C. Leonardi may publish in the future.

Co-authorship network of co-authors of C. Leonardi

This figure shows the co-authorship network connecting the top 25 collaborators of C. Leonardi. A scholar is included among the top collaborators of C. Leonardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Leonardi. C. Leonardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernandez, Anthony P., E. Daudén, Sascha Gerdes, et al.. (2022). Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2. Journal of the European Academy of Dermatology and Venereology. 36(10). 1774–1783. 15 indexed citations

Leonardi, C., Richard B. Warren, Kyoungah See, et al.. (2021). 649 Validation of the Optimal Psoriasis Assessment Tool (OPAT) as a method of assessing psoriasis severity and impact from physician and patient perspectives. Journal of Investigative Dermatology. 141(5). S113–S113. 4 indexed citations

Gordon, Kenneth B., Richard B. Warren, Alice B. Gottlieb, et al.. (2020). Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2). British Journal of Dermatology. 184(4). 652–662. 14 indexed citations

Blauvelt, Andrew, C. Leonardi, Boni E. Elewski, et al.. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184(6). 1047–1058. 73 indexed citations

Strober, Bruce, Alan Menter, C. Leonardi, et al.. (2020). Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal of the European Academy of Dermatology and Venereology. 34(12). 2830–2838. 41 indexed citations

Reich, Kristian, Phoebe Rich, Catherine Maari, et al.. (2019). Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study. British Journal of Dermatology. 181(1). 88–95. 57 indexed citations

Takeshita, Junko, Matthias Augustin, E.M.G.J. de Jong, et al.. (2019). 857 Psoriasis-related quality-of-life differs by race/ethnicity. Journal of Investigative Dermatology. 139(5). S148–S148. 2 indexed citations

Deodhar, Atul, Iain B. McInnes, Xenofon Baraliakos, et al.. (2019). Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 21(1). 111–111. 215 indexed citations

Blauvelt, Andrew, J.‐P. Lacour, Joseph F. Fowler, et al.. (2018). Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. British Journal of Dermatology. 179(3). 623–631. 109 indexed citations

10.

Papp, Kim, C. Leonardi, Andrew Blauvelt, et al.. (2017). Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology. 178(3). 674–681. 77 indexed citations

11.

Papp, Kim, Robert Bissonnette, Mamitaro Ohtsuki, et al.. (2016). 059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials. Journal of Investigative Dermatology. 136(9). S170–S170. 2 indexed citations

12.

Tsai, Tsen‐Fang, Vincent Ho, Michael Song, et al.. (2012). The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. British Journal of Dermatology. 167(5). 1145–1152. 65 indexed citations

13.

Leonardi, C., Jeffrey M. Sobell, Jeffrey Crowley, et al.. (2012). Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. British Journal of Dermatology. 167(3). 658–667. 34 indexed citations

14.

Leonardi, C., et al.. (2008). Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. British Journal of Dermatology. 158(5). 1107–1116. 62 indexed citations

15.

Elewski, Boni E., C. Leonardi, Alice B. Gottlieb, et al.. (2006). Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. British Journal of Dermatology. 156(1). 138–142. 31 indexed citations

16.

Tom, Wynnis L., et al.. (2006). Efalizumab-induced autoimmune pancytopenia. British Journal of Dermatology. 155(5). 1045–1047. 13 indexed citations

17.

Leonardi, C., et al.. (1998). Diagnosis and treatment of a case of cutaneous cytomegalovirus infection with a dramatic clinical presentation. Journal of the American Academy of Dermatology. 38(2). 349–351. 24 indexed citations

18.

Berger, T G, William S. Sawchuk, C. Leonardi, et al.. (1991). Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease. British Journal of Dermatology. 124(1). 79–83. 61 indexed citations

19.

Leonardi, C., et al.. (1991). Trichilemmomas are not associated with human papillomavirus DNA. Journal of Cutaneous Pathology. 18(3). 193–197. 28 indexed citations

20.

Penneys, Neal S. & C. Leonardi. (1991). Polymerase chain reaction: relevance for dermatopathology. Journal of Cutaneous Pathology. 18(1). 3–7. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact